دورية أكاديمية
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity.
| العنوان: | Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity. |
|---|---|
| المؤلفون: | van Dam KPJ; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands., Volkers AG; Department of Gastroenterology and Hepatology, Location Academic Medical Center, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Wieske L; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.; Department of Clinical Neurophysiology, St Antonius Hospital, Nieuwegein, The Netherlands., Stalman EW; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands., Kummer LYL; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, the Netherlands., van Kempen ZLE; Department of Neurology, Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands., Killestein J; Department of Neurology, Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands., Tas SW; Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Department of Rheumatology and Clinical Immunology, University of Amsterdam, Amsterdam, the Netherlands., Boekel L; Amsterdam Rheumatology and Immunology Center, Location Reade, Department of Rheumatology, Amsterdam, the Netherlands., Wolbink GJ; Amsterdam Rheumatology and Immunology Center, Location Reade, Department of Rheumatology, Amsterdam, the Netherlands., van der Kooi AJ; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands., Raaphorst J; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands., Takkenberg RB; Department of Gastroenterology and Hepatology, Location Academic Medical Center, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., D'Haens GRAM; Department of Gastroenterology and Hepatology, Location Academic Medical Center, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Spuls PI; Department of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands., Bekkenk MW; Department of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands., Musters AH; Department of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands., Post NF; Department of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands., Bosma AL; Department of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands., Hilhorst ML; Department of Internal Medicine, Section of Nephrology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands., Vegting Y; Department of Internal Medicine, Section of Nephrology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands., Bemelman FJ; Department of Internal Medicine, Section of Nephrology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands., Voskuyl AE; Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, the Netherlands., Broens B; Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, the Netherlands., Sanchez AP; Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Department of Rheumatology and Clinical Immunology, University of Amsterdam, Amsterdam, the Netherlands.; Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, the Netherlands., van Els CACM; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.; Faculty of Veterinary Medicine, Utrecht University Utrecht, Utrecht, The Netherlands., de Wit J; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands., Rutgers A; Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands., de Leeuw K; Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands., Horváth B; Department of Dermatology, Center for Blistering Diseases, University Medical Center Groningen, University Groningen, Groningen, The Netherlands., Verschuuren JJGM; Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands., Ruiter AM; Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands., van Ouwerkerk L; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands., van der Woude D; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands., Allaart RCF; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands., Teng YKO; Centre of Expertise for Lupus-, Vasculitis- and Complement-Mediated Systemic Diseases, Department of Internal Medicine - Nephrology section, Leiden University Medical Centre, Leiden, The Netherlands., van Paassen P; Department of Nephrology and Clinical Immunology, Maastricht University Medical Center, Maastricht, The Netherlands., Busch MH; Department of Nephrology and Clinical Immunology, Maastricht University Medical Center, Maastricht, The Netherlands., Jallah PBP; Department of Nephrology and Clinical Immunology, Maastricht University Medical Center, Maastricht, The Netherlands., Brusse E; Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands., van Doorn PA; Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands., Baars AE; Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands., Hijnen DJ; Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands., Schreurs CRG; Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands., van der Pol WL; Department of Neurology and Neurosurgery, Brain Center UMC Utrecht, Utrecht, the Netherlands., Goedee HS; Department of Neurology and Neurosurgery, Brain Center UMC Utrecht, Utrecht, the Netherlands., Steenhuis M; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, the Netherlands., Keijzer S; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, the Netherlands., Keijser JBD; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, the Netherlands., Cristianawati O; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, the Netherlands., Ten Brinke A; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, the Netherlands., Verstegen NJM; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, the Netherlands., van Ham SM; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, the Netherlands.; Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, the Netherlands., Rispens T; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, the Netherlands., Kuijpers TW; Department of Pediatric Immunology, Rheumatology and Infectious Disease, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, the Netherlands., Löwenberg M; Department of Gastroenterology and Hepatology, Location Academic Medical Center, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Eftimov F; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands. f.eftimov@amsterdamumc.nl. |
| مؤلفون مشاركون: | T2B! Immunity against SARS-CoV-2 study group |
| المصدر: | BMC infectious diseases [BMC Infect Dis] 2023 May 17; Vol. 23 (1), pp. 332. Date of Electronic Publication: 2023 May 17. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : BioMed Central, [2001- |
| مواضيع طبية MeSH: | COVID-19*, Humans ; SARS-CoV-2 ; Immunity, Humoral ; Prospective Studies ; Tumor Necrosis Factor Inhibitors ; Immunosuppressive Agents/therapeutic use ; Tumor Necrosis Factor-alpha ; Vaccination ; Antibodies, Viral |
| مستخلص: | Background: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressants (ISPs) may have impaired long-term humoral immune responses and increased disease activity after SARS-CoV-2 infection. We aimed to investigate long-term humoral immune responses against SARS-CoV-2 and increased disease activity after a primary SARS-CoV-2 infection in unvaccinated IMID patients on ISPs. Methods: IMID patients on active treatment with ISPs and controls (i.e. IMID patients not on ISP and healthy controls) with a confirmed SARS-CoV-2 infection before first vaccination were included from an ongoing prospective cohort study (T2B! study). Clinical data on infections and increased disease activity were registered using electronic surveys and health records. A serum sample was collected before first vaccination to measure SARS-CoV-2 anti-receptor-binding domain (RBD) antibodies. Results: In total, 193 IMID patients on ISP and 113 controls were included. Serum samples from 185 participants were available, with a median time of 173 days between infection and sample collection. The rate of seropositive IMID patients on ISPs was 78% compared to 100% in controls (p < 0.001). Seropositivity rates were lowest in patients on anti-CD20 (40.0%) and anti-tumor necrosis factor (TNF) agents (60.5%), as compared to other ISPs (p < 0.001 and p < 0.001, respectively). Increased disease activity after infection was reported by 68 of 260 patients (26.2%; 95% CI 21.2-31.8%), leading to ISP intensification in 6 out of these 68 patients (8.8%). Conclusion: IMID patients using ISPs showed reduced long-term humoral immune responses after primary SARS-CoV-2 infection, which was mainly attributed to treatment with anti-CD20 and anti-TNF agents. Increased disease activity after SARS-CoV-2 infection was reported commonly, but was mostly mild. Trial Registration: NL74974.018.20, Trial ID: NL8900. Registered on 9 September 2020. (© 2023. The Author(s).) |
| References: | Autoimmun Rev. 2022 Jan;21(1):102927. (PMID: 34474172) Elife. 2022 Jul 15;11:. (PMID: 35838348) Gut. 2021 May;70(5):865-875. (PMID: 33753421) BMC Med. 2022 Mar 2;20(1):100. (PMID: 35236350) J Med Virol. 2022 Dec;94(12):5780-5789. (PMID: 35945627) Mult Scler Relat Disord. 2021 Oct;55:103153. (PMID: 34392059) Science. 2020 Dec 4;370(6521):1227-1230. (PMID: 33115920) J Neurol. 2018 Jun;265(6):1251-1258. (PMID: 29372387) JAMA Neurol. 2021 Jul 1;78(7):880-882. (PMID: 33929488) Lancet Rheumatol. 2022 Jun;4(6):e417-e429. (PMID: 35527808) Rheumatology (Oxford). 2022 May 5;61(5):1928-1935. (PMID: 34352079) N Engl J Med. 2022 Jun 9;386(23):2201-2212. (PMID: 35613036) Semin Arthritis Rheum. 2022 Aug;55:152025. (PMID: 35617780) J Crohns Colitis. 2022 Mar 14;16(3):389-397. (PMID: 34473254) Lancet Rheumatol. 2022 Sep;4(9):e614-e625. (PMID: 35966645) Clin Transl Immunology. 2021 May 16;10(5):e1285. (PMID: 34026115) Lancet Rheumatol. 2022 May;4(5):e338-e350. (PMID: 35317410) Nat Rev Immunol. 2021 Jun;21(6):395-404. (PMID: 33927374) J Autoimmun. 2021 Feb;117:102580. (PMID: 33338707) RMD Open. 2021 Jul;7(2):. (PMID: 34312307) J Immunol. 2020 Dec 15;205(12):3491-3499. (PMID: 33127820) Cytokine. 2022 Jun;154:155873. (PMID: 35461172) J Rheumatol. 2013 Apr;40(4):469-75. (PMID: 23418385) J Am Soc Nephrol. 2021 May 3;32(5):1033-1036. (PMID: 33637518) Mult Scler Relat Disord. 2021 Jul;52:103014. (PMID: 34000684) RMD Open. 2022 Apr;8(1):. (PMID: 35383121) N Engl J Med. 2020 Sep 10;383(11):1085-1087. (PMID: 32706954) Lancet Rheumatol. 2022 Jun;4(6):e384-e387. (PMID: 35403000) |
| معلومات مُعتمدة: | 10430072010007 Netherlands ZONMW_ ZonMw |
| فهرسة مساهمة: | Keywords: Antibodies; Autoimmune disease; Covid-19; Disease activity; Flare; Immune-mediated inflammatory diseases; Immunity; Immunosuppression; SARS-CoV-2; TNF |
| المشرفين على المادة: | 0 (Tumor Necrosis Factor Inhibitors) 0 (Immunosuppressive Agents) 0 (Tumor Necrosis Factor-alpha) 0 (Antibodies, Viral) |
| تواريخ الأحداث: | Date Created: 20230517 Date Completed: 20230519 Latest Revision: 20230522 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10189216 |
| DOI: | 10.1186/s12879-023-08298-6 |
| PMID: | 37198536 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1471-2334 |
|---|---|
| DOI: | 10.1186/s12879-023-08298-6 |